AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

IART · NASDAQ · Medical - Devices

Integra LifeSciences (IART)

Builds neurosurgery, ENT, surgical-instrument and regenerative tissue products.

$16.02

After hours+0.01 (+0.06%)

At close$16.01(+2.69%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	382	397	369	418	381	443	383	416	402	435	392	419
Cost of revenue	164	171	162	192	181	194	188	206	176	220	168	199
Gross profit	218	226	207	226	200	249	194	209	226	215	224	220
	192	190	203	229	208	213	210	722	186	−341	184	200
Research & development	27	24	27	30	27	31	25	27	22	25	24	24
Selling, general & administrative	162	163	166	195	177	179	181	180	169	169	178	172
Other expenses	3	3	10	4	4	4	4	515	−6	−535	−18	4
Operating income	27	36	4	−3	−8	36	−15	−513	40	556	40	19
	−8	−7	−9	−12	−12	−13	−15	−18	−47	−552	−42	−15
Interest income	5	5	5	5	5	5	2	5	5	4	1	4
Interest expense	13	14	14	19	19	19	20	21	23	24	27	23
Other non-operating income	−5	−7	−4	−6	−7	−6	−4	−3	24	528	16	−8
Income before tax	19	29	−5	−15	−20	23	−30	−531	−7	4	−2	5
Income tax expense	−1	9	−2	−3	−10	3	−5	−47	−1	6	2	0
Net income from continuing operations	19	20	−3	−12	−11	19	−25	−484	−5	−2	−5	4
Net income	19	20	−3	−12	−11	19	−25	−484	−5	−2	−5	4
EPS, basic	$0.24	$0.25	−$0.04	−$0.16	−$0.14	$0.25	−$0.33	−$6.33	−$0.07	−$0.02	−$0.06	$0.06
EPS, diluted	$0.24	$0.25	−$0.04	−$0.16	−$0.14	$0.25	−$0.33	−$6.33	−$0.07	−$0.02	−$0.06	$0.06
Weighted average shares, basic	80	78	78	77	76	77	76	76	77	77	77	78
Weighted average shares, diluted	80	78	78	77	76	77	76	76	77	77	77	78
EBITDA	62	74	39	40	35	79	26	−472	54	66	63	66
Depreciation & amortization	31	31	31	37	36	37	37	38	38	38	38	38
EBIT	32	43	8	3	−1	42	−11	−510	16	28	24	28